Contribute Try STAT+ Today

Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot campus, where the official mascot is sniffing about in search of varmint. As for us, we are as busy as ever hunting and gathering items of interest. We trust you have your own hectic agendas. So join us as we hoist the ever-present cup of stimulation and attack the to-do list. Have a grand day, everyone, and do stay in touch. …

After two years of contentious bargaining, a U.S. bankruptcy court judge approved a controversial plan that will dissolve Purdue Pharma, which has been blamed for triggering a widespread opioid crisis, and shield members of the Sackler family who control the company from future lawsuits, STAT reports. The settlement calls for some Sackler family members to contribute more than $4.3 billion over a decade to compensate people, local governments, and tribal communities that were harmed by the OxyContin painkiller. Appeals are expected.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment